{'fraction_non_alphanumeric': 0.02348993288590604, 'fraction_numerical': 0.0025167785234899327, 'mean_word_length': 5.740112994350283, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Epidermoid carcinoma-cell culture supernatant's inhibition of monocyte chemotaxis: evidence for a tumour-mediated effect.

Epidermoid carcinoma-cell culture supernatants obtained from three laryngeal-epidermoid carcinoma patients were tested in the monocyte suspensions of 13 stage I and stage II (TNM) head and neck epidermoid-carcinoma patients and seven healthy controls for its chemotactic inhibitor activity in vitro with a modified Boyden chamber method. Using 2% casein as the chemoattractant, mean values of monocyte chemotaxis and random migration were found to be decreased in the patient group compared to the controls in a simultaneous assay recorded by the "leading front" method. Simultaneous experiments performed with the supernatant revealed a nearly double-fold increase in random migration and depressed chemotaxis in both groups. The supernatant caused a further depression in the chemotaxis of the patients' already-disabled monocytes, which is thought to be representative for advanced stage tumours. The depression of monocyte chemotaxis, especially in the control group, implies the presence of tumour-derived chemotactic inhibitor(s) for monocytes in the supernatant.